<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134626</url>
  </required_header>
  <id_info>
    <org_study_id>simvhp01</org_study_id>
    <nct_id>NCT02134626</nct_id>
  </id_info>
  <brief_title>Simvastatin Effect on Portal Hypertension</brief_title>
  <official_title>Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ItÂ´s a clinical research of the effects in portal hypertension caused by simvastatin. We are
      going to use the hepatic venous pressure gradient(HVPG) measurement and the azygos flow at
      echoendoscopy to evaluate the benefits of the drug. Preliminary studies demonstrated that
      simvastatin can lower portal pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The simvastatin can target the liver enhancing nitric oxide intra-hepatic and lowering
      resistance that may be responsible for most of cirrhosis complications. Indeed, the potential
      use of this drug may ameliorate the HVPG and azygos flow. Portal hypertension is responsible
      for most of the cases of death in cirrhosis. The esophageal varices, ascites and hepatorenal
      syndrome are the most harmful consequences of cirrhosis that should be prevented. In that
      way, simvastatin appears as a promising therapy.The study will include two groups of patients
      using aleatory randomization and one group will receive simvastatin while the other will
      receive placebo blindly. At the start and at the end of the study the patients will be
      submitted to HVPG measurement and azygous vein flow measure.

      The endpoints will be the normalization of HVPG or lower significantly(20% or more.

      The patients will be followed for 6 months after the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic venous pressure gradient (HVPG) in mmHg units</measure>
    <time_frame>3 months</time_frame>
    <description>Positive results consist of reduction of the HVPG to values equal or less than 12 mmHg or 20% lower than the first measure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Esophageal Varices</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1: Simvastatin 40mg / pill, one pill once a day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2: Placebo one pill once a day for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40mg / pill, one pill orally once a day for three months</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Portal hypertension: esophageal varices, ascites, splenomegaly or hepatorenal
             syndrome.

        Exclusion Criteria:

          -  Child-Pugh C decompensated or encephalopathy

          -  Malignancy except basocellular cancer

          -  Hepatocarcinoma

          -  Anti-viral therapy

          -  HIV

          -  Prevention of digestive hemorrhage with band ligation or sclerotherapy for the last 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priscila Pollo-Flores, MD, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Rio de Janeiro - UFRJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Guilherme Rezende</investigator_full_name>
    <investigator_title>Associate Professor of the Medical Faculty</investigator_title>
  </responsible_party>
  <keyword>Portal Hypertension</keyword>
  <keyword>Hepatic Venous Pressure Gradient</keyword>
  <keyword>Esophageal Varices</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>HVPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

